Emergex combines validated technologies together with the very latest scientific insights to develop its vaccines:
- Emergex has successfully generated a 1st generation human-specific MHC class I CD8 peptide ‘ligandome’ library for Dengue, Influenza, Zika, Hepatitis B and Francisella tularensis, i.e. pathogen-derived peptides known to be presented to CD8+ T cells in the context of MHC class I molecules on the surface of pathogen-infected cells. The peptides are presented by the most commonly occurring HLA alleles, allowing for an estimated 95% population coverage by vaccine peptides. The ‘ligandome’ library contains encrypted peptide data to instruct the immune system to increase the frequency of pathogen-specific T cells, thereby increasing the base level of pathogen-specific immunity. Upon subsequent encounter with the pathogen, the immune system will have been pre-programmed to response more rapidly and with a larger number of pathogen-specific T cells. This will potentially reduce disease severity but still allow natural immunity to provide long-term protection.
- Experimentally-validated peptides are combined with a quantum-sized nanocluster that can directly deliver them to the naive immune system and programme it to eliminate pathogen-infected cells upon subsequent exposure and infection. It is the combination of these technologies that produces a T-Cell Adaptive Vaccine, capable of delivering the right peptides to the right place, in order to induce a strong T cell immune response that will target and kill infected cells.
- Emergex’s vaccines are suited to be administered by novel microneedle technologies.
- Emergex’s vaccines do not need an adjuvant and potentially avoid allergic, autoimmune or antibody-mediated side effects, limitations associated with traditional vaccines.
